Smith & Nephew plc (LON:SN) Given Consensus Rating of “Hold” by Brokerages

Shares of Smith & Nephew plc (LON:SN) have received an average rating of “Hold” from the seven analysts that are currently covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is GBX 1,185.86.

SN has been the subject of a number of recent research reports. Royal Bank Of Canada cut Smith & Nephew to a “sector perform” rating and set a GBX 1,350 price objective for the company. in a research report on Thursday, May 7th. UBS Group reissued a “neutral” rating and set a GBX 1,300 target price on shares of Smith & Nephew in a research note on Tuesday, May 5th. Finally, Berenberg Bank reissued a “hold” rating and set a GBX 13 target price on shares of Smith & Nephew in a research note on Friday, May 1st.

Smith & Nephew Trading Up 2.7%

Smith & Nephew stock opened at GBX 1,103 on Thursday. The stock’s fifty day moving average is GBX 1,211.05 and its 200 day moving average is GBX 1,248.86. The company has a quick ratio of 0.84, a current ratio of 2.57 and a debt-to-equity ratio of 62.90. The firm has a market cap of £12.09 billion, a PE ratio of 39.71, a price-to-earnings-growth ratio of 0.46 and a beta of 0.67.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.